Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

NeuroOne Medical Technologies Corporation (NMTC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6900+0.1100 (+6.96%)
At close: 04:00PM EDT
1.6500 -0.04 (-2.37%)
After hours: 06:23PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.5800
Open1.5600
Bid1.5000 x 1300
Ask1.8200 x 900
Day's Range1.5600 - 1.7400
52 Week Range0.5100 - 4.2300
Volume20,968
Avg. Volume199,377
Market Cap27.394M
Beta (5Y Monthly)0.53
PE Ratio (TTM)N/A
EPS (TTM)-0.8250
Earnings DateDec 13, 2022 - Dec 19, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NMTC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NeuroOne Medical Technologies C
    Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
    Rating
    Fair Value
    Economic Moat
    11 days agoMorningstar
View more
  • PR Newswire

    NeuroOne Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announced that, effective September 20, 2022, the Compensation Committee of the Board of Directors approved two equity awards under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the "Inducement Plan"), as a material inducement to the individuals en

  • PR Newswire

    NeuroOne® Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

    NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the third quarter of fiscal year 2022 ended June 30, 2022.

  • PR Newswire

    NeuroOne® Submits Special 510(k) to FDA for Evo® sEEG Electrode

    NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the Company submitted a special 510(k) to the U.S. Food and Drug Administration ("FDA") on August 8th for its sEEG electrode to extend the duration of use from less than 24 hours to less than 30 day use. A special 510(k), according to FDA guidance, is us

Advertisement
Advertisement